# National Research Corporation (NRC) Stock Analysis: A Look at Its 51.24% Return on Equity in the Healthcare Sector

- Link: https://www.directorstalkinterviews.com/national-research-corporation-nrc-stock-analysis-a-look-at-its-51-24-return-on-equity-in-the-healthcare-sector/4121244150
- Published: 2026-03-12T11:26:46+00:00
- Author: Madison Wilson

For investors seeking opportunities within the healthcare sector, National Research
Corporation (NRC) presents a unique proposition. Known for its comprehensive analytics
and insights aimed at enhancing patient and employee experiences, NRC operates at
the intersection of healthcare services and information technology. With a market
capitalization of $362.75 million, this company, headquartered in Lincoln, Nebraska,
offers a suite of solutions designed to empower healthcare organizations across 
the United States.

Currently trading at $16.01, NRC’s stock has seen its price fluctuate between $10.13
and $22.48 over the past year. Despite a recent slight dip of -0.02%, the stock 
shows resilience, with its 200-day moving average standing at $15.54, slightly below
the current price point. This indicates a modest upward trend over the longer term.
However, the 50-day moving average of $17.04 reflects recent pressures on the stock.

One standout metric for NRC is its impressive Return on Equity (ROE) of 51.24%. 
This figure is significant in the context of the healthcare industry, showcasing
the company’s ability to effectively generate profits from its shareholders’ equity.
This strong ROE suggests that NRC is adept at turning its equity investments into
substantial gains, a reassuring signal for potential investors considering the company’s
capacity for generating shareholder value.

However, the company faces challenges, as evidenced by a reported revenue growth
decline of -4.60%. This contraction points to potential headwinds in the market 
experience solutions and patient experience solutions segments, both pivotal to 
NRC’s business model. Despite this, the company’s earnings per share (EPS) of $0.50
indicates profitability, albeit with room for improvement.

A key point of consideration for dividend-focused investors is NRC’s dividend yield
of 3.50%, which is relatively attractive in the current market environment. However,
the payout ratio stands at a concerning 104.00%, suggesting that the company is 
distributing more in dividends than it earns in net income. This could potentially
impact future dividend [sustainability](https://www.directorstalkinterviews.com/sustainability-green-stocks-news)
unless earnings improve.

From a technical perspective, NRC’s RSI (Relative Strength Index) of 32.55 suggests
that the stock is approaching oversold territory, which might indicate a potential
buying opportunity for contrarian investors. The MACD (Moving Average Convergence
Divergence) at -0.37, with a signal line at -0.94, further reinforces the current
bearish momentum, suggesting cautious optimism for those considering entry points
based on technical indicators.

Analyst coverage for NRC is notably absent, with no buy, hold, or sell ratings, 
and no established target price range. This lack of coverage could mean that NRC
is flying under the radar, presenting an opportunity for investors willing to do
their own due diligence.

National Research Corporation continues to leverage its technology-driven solutions
to support healthcare organizations in enhancing patient and employee experiences.
With innovative offerings like the AI engine Huey, NRC remains committed to fostering
human understanding in healthcare. As the company navigates its current challenges,
investors will need to weigh NRC’s robust ROE and dividend yield against its revenue
growth concerns and payout ratio. For those with a keen eye on long-term value creation
in the healthcare sector, NRC warrants a closer look.

Share on: